DURHAM, N.C. (JUNE 26, 2019) - Results of a phase 1 clinical trial released today in STEM CELLS Translational Medicine (SCTM) have identified a specific line of human neural stem cells that shows potential for helping recover motor function in those who suffer a hemiparetic stroke (where one side of the body is left weak or paralyzed).
You are here
Press Releases from AlphaMed Press
June 26, 2019
June 25, 2019
DURHAM, N.C. (JUNE 25, 2019) - A study released today in STEM CELLS identifies a possible new way to regrow hair. The research demonstrates how extracellular vesicles (EVs), isolated from stimulated dermal fibroblasts, promote hair growth via their secretion of the protein norrin — and how norrin is a key player in growing hair.
The discovery could lead to numerous therapeutic treatments for alopecia (hair loss), the researchers say.
June 20, 2019
DURHAM, N.C. ( JUNE 20, 2019 ) - A study released today in STEM CELLS Translational Medicine (SCTM) demonstrates how preconditioning mesenchymal stem cells (MSCs) enhances their ability to treat acute respiratory distress disorder (ARDS). This important information could point to a way to developing more effective MSC treatments for clinical application, according to Ben Antebi, Ph.D., who led the team of investigators from the U.S. Army Institute of Surgical Research and Stanford University.
June 11, 2019
DURHAM, N.C. JUNE 11, 2019 - A study released today in STEM CELLS demonstrates how extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying their gene expression and increasing their viability and cloning ability. In a test on mice, MSC-EVs also increased the cells’ ability to lodge into bone marrow. This research performed by Prof. Sanchez-Guijo’s Lab at the IBSAL-University of Salamanca (Spain) could potentially overcome serious complications due to graft failure or poor engraftment from allogeneic stem cell transplantation.
June 1, 2019
DURHAM, N.C. (MAY 30, 2019) - A study released today in STEM CELLS Translational Medicine is the first to demonstrate an efficient delivery system for the sustained release of human placental stem cell (HPSC)-derived conditioned medium (CM) to treat acute kidney injuries. The platelet-rich plasma-based gel system was able to deliver CM into the injured kidney, where it helped restore function and regenerate injured tissue.
May 14, 2019
DURHAM, N.C. (MAY 14, 2019) - A study recently published in STEM CELLS shows a new method for accelerating human pluripotent stem cell-derived cardiomyocytes’ (hPSC-CMs) development. If a way can be found to overcome hPSC-CMs’ developmental immaturity, which leaves them functionally and structurally different from mature human cardiomyocytes, they can be powerful tools for disease modeling, drug development, basic research and new therapies. This study shows great promise in resolving this issue.
April 11, 2019
DURHAM, N.C. (APRIL 11, 2019) - A study released today in STEM CELLS shows how a new class of cancer drugs, called Smac mimetics, is effective in killing off the stem cells that lead to glioblastoma (GBM) depending on oxygen level. This might help pave the way to a new, more efficient method for treating the most common and aggressive form of brain cancer in adults.
April 9, 2019
DURHAM, N.C. (APRIL 09, 2019) - Stem cells collected from the patient’s own bone marrow holds great interest as a potential therapy for osteoarthritis of the knee (KOA) because of their ability to regenerate the damaged cartilage. The results were released today in STEM CELLS Translational Medicine (SCTM).
March 26, 2019
DURHAM, N.C. MARCH 26, 2019 - The potential for stem cells to reduce damage, regenerate tissue and promote functional recovery after a spinal cord injury (SCI) is being tested in several ongoing clinical trials. However, a new study released today in STEM CELLS Translational Medicine (SCTM) indicates that donor age-dependent stem cell therapy could help optimize cell treatment strategies for clinical translation.
February 26, 2019
Durham, NC – A groundbreaking study released today in STEM CELLS Translational Medicine shows that the gold standard for obtaining stem cells to use in transplantation therapy – harvesting them from the patient himself – is not the best way to go when attempting to regenerate bone in a person with type 1 diabetes.
Type 1 diabetes is linked to low bone density, which greatly increases the risk of fractures. Researchers don’t know exactly why — it might be that insulin, which is deficient in the disease, promotes bone growth and strength – but all agree that finding a way to address this issue is important.
